When was Rystiggo approved by the FDA?

Written by Marta Figueiredo, PhD | July 7, 2023

When was Rystiggo approved by the FDA?

Category: Rystiggo

The U.S. Food and Drug Administration (FDA) approved Rystiggo in June 2023 as a treatment for adults with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor or muscle-specific kinase — the two most common types of disease-driving antibodies. The approval made Rystiggo the first therapy available for the two most common gMG subtypes.

Print This Article

About the Author

Marta Figueiredo, PhD Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology, and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France. She has also authored several research papers published in peer-reviewed international scientific journals. Joana joined Bionews in 2018, starting as a science writer, then moving to a science editor position in 2020, and to editorial associate director of resource pages in 2025.